Filing Flows › Insmed (INSM) › R&D spending
Insmed (INSM) R&D spending by quarter
Insmed's R&D spending was $270M in Q3 2026 (third quarter 2026), +6% from Q4 2025. Over the last 5 quarters it ranged from $153M (Q1 2025) to $270M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $270M | +6% | +45% |
| Q4 2025 | $255M | +37% | — |
| Q3 2025 | $186M | +5% | — |
| Q2 2025 | $177M | +16% | — |
| Q1 2025 | $153M | — | — |
Q3 2026 at a glance
Insmed, Q3 2026: revenue $524M (+268% year over year), operating margin -17.0%, net loss $100M, operating cash flow −$36.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Insmed's R&D spending?
Insmed's R&D spending was $270M in Q3 2026 (third quarter 2026), +6% from Q4 2025.
How has Insmed's R&D spending changed?
Over the last 5 quarters it ranged from $153M (Q1 2025) to $270M (Q3 2026).